Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/mdr.2022.0216 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful Treatment of Severe Tuberculosis With Contezolid Add-On Regimen in a Patient Complicated With Acute Thrombocytopenia: A Case Report.
Clin Case Rep
December 2024
Department of Tuberculosis, 905th Hospital of PLA Navy Naval Medical University Shanghai China.
Polypharmacy in managing severe tuberculosis patients usually poses a risk of adverse drug reactions. Contezolid is a new oxazolidinone antibiotic showing good in vitro and in vivo activity against . Contezolid add-on regimen shows promising efficacy and safety results in managing severe tuberculosis patients complicated with acute thrombocytopenia.
View Article and Find Full Text PDFThe clinically relevant MEK inhibitor mirdametinib combined with D-cycloserine and prediction error disrupts fear memory in PTSD models.
Transl Psychiatry
December 2024
School of Psychological Sciences, College of Health and Medicine, University of Tasmania, Tasmania, TAS, Australia.
This study establishes mirdametinib as the first MEK inhibitor that can undergo clinical development for psychiatric indications such as post-traumatic stress disorder (PTSD). PTSD is characterized by persistent traumatic memories with limited effective treatment options. A body of evidence suggests that memory storage is dynamic and constantly updated through post-retrieval modification a process termed reconsolidation.
View Article and Find Full Text PDFStructural toxicity relationship (STR) of linezolid to mitigate myelosuppression and serotonergic toxicity.
Bioorg Med Chem
November 2024
Division of Computer Aided Drug Design, Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule 425405, Maharashtra, India. Electronic address:
Article Synopsis
- * Linezolid is an effective drug in the BPaL regimen for treating these resistant TB strains, but its use can be limited due to side effects like myelosuppression and MAO inhibition.
- * Research is focusing on modifying Linezolid and its analogues to reduce toxic effects while maintaining their antibacterial effectiveness, leading to the development of safer alternatives for treating drug-resistant TB.
Copper inactivates DcsB by oxidizing the metal ligand Cys86 to sulfinic acid.
FEBS J
December 2024
Faculty of Pharmacy, Yasuda Women's University, Hiroshima, Japan.
N-hydroxy-l-arginine amidinohydrolase (EC:3.5.3.
View Article and Find Full Text PDFAdvancements in NMDA Receptor-Targeted Antidepressants: From d-Cycloserine Discovery to Preclinical Efficacy of Lu AF90103.
J Med Chem
November 2024
Neuroscience Drug Discovery Denmark, H. Lundbeck A/S, 9 Ottiliavej, Valby, DK-2500 Copenhagen, Denmark.
The discovery of d-cycloserine (), a partial agonist of the NMDA receptor that exhibits antidepressant effects without the psychotomimetic effects of ketamine, has fueled interest in new NMDA-targeting antidepressants. Our objective was to identify potent partial agonists mirroring , particularly tailored for the GluN2B subtype of the NMDA receptor. Through a structure-based drug design approach, we discovered compound .
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!